Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-κB pathways in human cholangiocarcinomas both in vitro and in vivo

Xu,Dongsheng; Ma,Yong; Zhao,Baolei; Li,Shuai; Zhang,Yu; Pan,Shangha; Wu,Yaohua; Wang,Jizhou; Wang,Dawei; Pan,Huayang; Liu,Lianxin; Jiang,Hongchi

doi:10.3892/or.2014.3059

Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-κB pathways in human cholangiocarcinomas both in vitro and in vivo

Authors:
- Dongsheng Xu
- Yong Ma
- Baolei Zhao
- Shuai Li
- Yu Zhang
- Shangha Pan
- Yaohua Wu
- Jizhou Wang
- Dawei Wang
- Huayang Pan
- Lianxin Liu
- Hongchi Jiang
View Affiliations

Affiliations: Key Laboratory of Hepatosplenic Surgery, Ministry of Education, Department of Hepatic Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Abdominal Ultrasound, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: March 5, 2014 https://doi.org/10.3892/or.2014.3059
Pages: 2063-2070

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cholangiocarcinoma (CCA) is a notoriously lethal tumor mostly due to the de novo or acquired resistance to traditional chemotherapy besides gemcitabine and, therefore, an increasing need for effective strategies to prevent and treat the poor prognosis of this tumor is required. Thymoquinone (TQ), a hopeful natural product derived from black cumin (Nigella sativa) has shown considerable antineoplastic properties. Whether TQ exerts antitumor effects on CCA cells in vitro and in vivo remains unknown. Examinations of cell viability assay, detection of cell cycle and apoptosis, electrophoretic mobility shift assay (EMSA), western blotting and immunohistochemistry were used in the present study. We demonstrated that TQ inhibited the growth of human CCA cell lines (TFK-1 and HuCCT1) in a dose- and time-dependent manner. Firstly, our results provided evidence that TQ not only inhibits the proliferation of CCA cells, induces cell cycle arrest and prompts cell apoptotic effect in vitro, but it also exhibits inhibitory effects of tumor growth and angiogenesis in vivo. The responsible mechanism is at least partially due to TQ inhibiting the growth of CCA cell lines induced by downregulation of PI3K/Akt and NF-κB and regulated gene products, including p-AKT, p65, XIAP, Bcl-2, COX-2, VEGF. Taken together, these results provide strong evidence of our hypothesis that TQ alone presents a promising therapeutic regimen for the treatment of CCA cells with better efficiency.

View Figures

View References

1	Ramírez-Merino N, Aix SP and Cortés-Funes H: Chemotherapy for cholangiocarcinoma: an update. World J Gastrointest Oncol. 5:171–176. 2013.
2	Patel T: Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 3:33–42. 2006. View Article : Google Scholar
3	Randi G, Malvezzi M, Levi F, et al: Epidemiology of biliary tract cancers: an update. Ann Oncol. 20:146–159. 2009. View Article : Google Scholar : PubMed/NCBI
4	Shin HR, Oh JK, Masuyer E, et al: Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 101:579–585. 2010. View Article : Google Scholar : PubMed/NCBI
5	Tyson GL and El-Serag HB: Risk factors for cholangiocarcinoma. Hepatology. 54:173–184. 2011. View Article : Google Scholar
6	de Groen PC, Gores GJ, LaRusso NF, Gunderson LL and Nagorney DM: Biliary tract cancers. N Engl J Med. 341:1368–1378. 1999.
7	Hezel AF and Zhu AX: Systemic therapy for biliary tract cancers. Oncologist. 13:415–423. 2008. View Article : Google Scholar : PubMed/NCBI
8	Sirica AE: Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology. 41:5–15. 2005. View Article : Google Scholar : PubMed/NCBI
9	Blechacz B and Gores GJ: Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 48:308–321. 2008. View Article : Google Scholar : PubMed/NCBI
10	Furuse J, Kasuga A, Takasu A, Kitamura H and Nagashima F: Role of chemotherapy in treatments for biliary tract cancer. J Hepatobiliary Pancreat Sci. 19:337–341. 2012. View Article : Google Scholar : PubMed/NCBI
11	Gali-Muhtasib H, Roessner A and Schneider-Stock R: Thymoquinone: a promising anti-cancer drug from natural sources. Int J Biochem Cell Biol. 38:1249–1253. 2006.PubMed/NCBI
12	Yi T, Cho SG, Yi Z, et al: Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther. 7:1789–1796. 2008. View Article : Google Scholar : PubMed/NCBI
13	Woo CC, Kumar AP, Sethi G and Tan KH: Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol. 83:443–451. 2012. View Article : Google Scholar : PubMed/NCBI
14	Attoub S, Sperandio O, Raza H, et al: Thymoquinone as an anticancer agent: evidence from inhibition of cancer cells viability and invasion in vitro and tumor growth in vivo. Fundam Clin Pharmacol. 27:557–569. 2013. View Article : Google Scholar : PubMed/NCBI
15	Banerjee S, Kaseb AO, Wang Z, et al: Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res. 69:5575–5583. 2009. View Article : Google Scholar : PubMed/NCBI
16	Shen HM and Tergaonkar V: NFκB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis. 14:348–363. 2009.
17	Schmitz KJ, Lang H, Wohlschlaeger J, et al: AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma. World J Gastroenterol. 13:6470–6477. 2007. View Article : Google Scholar : PubMed/NCBI
18	Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Reviews Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
19	Seubwai W, Vaeteewoottacharn K, Hiyoshi M, et al: Cepharanthine exerts antitumor activity on cholangiocarcinoma by inhibiting NF-κB. Cancer Sci. 101:1590–1595. 2010.PubMed/NCBI
20	Kim SH, Song SH, Kim SG, et al: Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-κB as a possible target. J Cancer Res Clin Oncol. 130:551–560. 2004.PubMed/NCBI
21	Jiang H, Ma Y, Chen X, et al: Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma. Cancer Sci. 101:975–983. 2010. View Article : Google Scholar : PubMed/NCBI
22	Ma Y, Wang J, Liu L, et al: Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-κB. Cancer Lett. 301:75–84. 2011.PubMed/NCBI
23	Liang Y, Zheng T, Song R, et al: Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. Hepatology. 57:1847–1857. 2013.PubMed/NCBI
24	Sun X, Jiang H, Jiang X, et al: Antisense hypoxia-inducible factor-1α augments transcatheter arterial embolization in the treatment of hepatocellular carcinomas in rats. Hum Gene Ther. 20:314–324. 2009.
25	Khan SA, Toledano MB and Taylor-Robinson SD: Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB. 10:77–82. 2008. View Article : Google Scholar : PubMed/NCBI
26	Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell. 108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
27	Tannock IF and Lee C: Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs. Br J Cancer. 84:100–105. 2001. View Article : Google Scholar : PubMed/NCBI
28	Sheppard K, Kinross KM, Solomon B, Pearson RB and Phillips WA: Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog. 17:69–95. 2012. View Article : Google Scholar : PubMed/NCBI
29	Samuels Y and Ericson K: Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 18:77–82. 2006. View Article : Google Scholar : PubMed/NCBI
30	Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 9:550–562. 2009. View Article : Google Scholar : PubMed/NCBI
31	Ewald F, Grabinski N, Grottke A, et al: Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer. 133:2065–2076. 2013. View Article : Google Scholar : PubMed/NCBI
32	DiDonato JA, Mercurio F and Karin M: NF-κB and the link between inflammation and cancer. Immunol Rev. 246:379–400. 2012.
33	Arlt A, Gehrz A, Müerköster S, et al: Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 22:3243–3251. 2003.